Daniel Zinicola, MD
General Practice · Rocky Point, NCNPI 1811991219
Payments from drug & device makers
Across 172 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$413
- Astellas Pharma US Inc$293
- Xeris Pharmaceuticals, Inc.$253
- Novo Nordisk$235
- Takeda Pharmaceuticals U.S.A., Inc.$194
- Boehringer Ingelheim$176
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,29497%
- Education$953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 20 | $413 |
| Astellas Pharma US Inc | 13 | $293 |
| Xeris Pharmaceuticals, Inc. | 13 | $253 |
| Novo Nordisk | 13 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $194 |
| Boehringer Ingelheim | 9 | $176 |
| AbbVie(2 entities) | 9 | $155 |
| Pfizer | 7 | $154 |
| AstraZeneca | 8 | $138 |
| Merck | 7 | $126 |
| GSK | 7 | $105 |
| Eisai Inc. | 6 | $100 |
| Antares Pharma, Inc. | 3 | $100 |
| Axsome Therapeutics, Inc. | 4 | $99 |
| Preventric Diagnostics, Inc. | 1 | $90 |
| Amgen(2 entities) | 4 | $76 |
| Lilly USA, LLC | 5 | $74 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Biogen | 3 | $51 |
| Bayer | 3 | $49 |
| Supernus Pharmaceuticals, Inc. | 2 | $47 |
| Mylan Specialty L.p. | 2 | $44 |
| Abbott | 2 | $43 |
| Corcept Therapeutics | 2 | $42 |
| Virtus Pharmaceuticals LLC | 1 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Exact Sciences | 1 | $31 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Corium, LLC | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
How this compares
$3,389 in reported general payments places this provider in the 95th percentile of 2,924 general practice providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $75,948 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $44,027 |
| OzempicSemaglutide | 37 | $36,086 |
| XareltoRivaroxaban | 44 | $28,503 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $22,985 |
| JanuviaSitagliptin Phosphate | 40 | $22,673 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $19,925 |
| TrulicityDulaglutide | 14 | $18,788 |
| Spiriva RespimatTiotropium Bromide | 27 | $17,892 |
| NamzaricMemantine Hcl/Donepezil Hcl | 11 | $11,276 |
| FarxigaDapagliflozin Propanediol | 14 | $10,047 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $9,615 |
| TrintellixVortioxetine Hydrobromide | 18 | $9,514 |
| Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm | 57 | $8,970 |
| Victoza 3-PakLiraglutide | 13 | $8,930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $154 | $80,556118 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $105 | $51,93180 claims |
| MerckJanumet, Januvia, Belsomra | $126 | $51,45168 claims |
| Novo NordiskOzempic | $235 | $36,08637 claims |
| Lilly USA, LLCTrulicity, Humulin 70-30 | $74 | $21,10034 claims |
| AstraZenecaFarxiga, Symbicort | $138 | $19,66239 claims |
| Boehringer IngelheimSpiriva Respimat | $176 | $17,89227 claims |
| AbbVieNamzaric | $155 | $11,27611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $194 | $9,51418 claims |
| Astellas Pharma US IncVeozah | $293 | $6,70112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,924 general practice providers in North Carolina.
Other general practice in Rocky Point
- Matthew MillerCharlotte$937K
- James BarberDurham$768K
- Robert LoweCharlotte$615K
- Howard JamesSanford$483K
- Clifton CameronFayetteville$404K
- Michael HarrisonRaleigh$249K
- Ronnie DavidsonMooresville$151K
- Leo HaydtHolly Springs$119K
- Andrew KellyGreensboro$115K
- Mark HymanGreensboro$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.